Teva Pharmaceutical Industries (NYSE: TEVA)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Teva Pharmaceutical Industries Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Teva Pharmaceutical Industries Company Info
A global pharmaceutical company, Teva develops, produces, and markets generic drugs covering all major treatment categories.
News & Analysis
Both have plans to return to growth.
Investors were disappointed with the drugmaker's 2023 outlook.
I own all six great businesses and don't plan to sell a single share.
A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals.
Sometimes, business models that sound safe still fail to deliver for shareholders.
A degree of uncertainty about the company's leadership compounded some rather discouraging recent developments.
There were two major developments with the company, both of which involved piles of money.
The generic drugs specialist settled one of a number of state lawsuits over its business practices.
TEVA earnings call for the period ending December 31, 2022.
TEVA earnings call for the period ending September 30, 2022.
TEVA earnings call for the period ending June 30, 2022.
TEVA earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.